Effect of magnesium level before allogeneic hematopoietic cell transplantation on outcome in acute leukemia

IF 1.6 4区医学 Q4 IMMUNOLOGY

Transplant immunology Pub Date : 2024-07-26 DOI:10.1016/j.trim.2024.102100

Qingqing Fan , Xiang Hui , Yu Zhang, Yongqing Wang

{"title":"Effect of magnesium level before allogeneic hematopoietic cell transplantation on outcome in acute leukemia","authors":"Qingqing Fan , Xiang Hui , Yu Zhang, Yongqing Wang","doi":"10.1016/j.trim.2024.102100","DOIUrl":null,"url":null,"abstract":"<div><p>This study assessed the effect of serum magnesium levels and their role in the outcome of allogeneic hematopoietic cell transplantation (allo-HSCT) in acute leukemia. Fifty-four patients with acute leukemia who underwent allo-HSCT were divided into two groups according to their serum magnesium levels before transplantation. The results showed that serum magnesium level is an independent factor influencing the prognosis of patients undergoing allo-HSCT. Low magnesium levels were associated with inferior overall survival and event-free survival compared with the associations of high magnesium levels (HR = 0.149; (95% CI: 0.029–0.755 for overall survival; HR = 0.369; 95% CI: 0.144–0.949, <em>p</em> = 0.039 for event-free survival). The competing risk model showed that the cumulative incidence of acute graft-versus-host disease was significantly low in the high magnesium group (<em>p</em> = 0.028). In general, there is a correlation between high magnesium levels and superior outcomes, including less and milder acute graft-versus-host disease, which does not affect cyclosporine-A levels. These findings provide valuable information for identifying the risk of poor prognosis in patients preparing for transplantation.</p></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"86 ","pages":"Article 102100"},"PeriodicalIF":1.6000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0966327424001163","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study assessed the effect of serum magnesium levels and their role in the outcome of allogeneic hematopoietic cell transplantation (allo-HSCT) in acute leukemia. Fifty-four patients with acute leukemia who underwent allo-HSCT were divided into two groups according to their serum magnesium levels before transplantation. The results showed that serum magnesium level is an independent factor influencing the prognosis of patients undergoing allo-HSCT. Low magnesium levels were associated with inferior overall survival and event-free survival compared with the associations of high magnesium levels (HR = 0.149; (95% CI: 0.029–0.755 for overall survival; HR = 0.369; 95% CI: 0.144–0.949, p = 0.039 for event-free survival). The competing risk model showed that the cumulative incidence of acute graft-versus-host disease was significantly low in the high magnesium group (p = 0.028). In general, there is a correlation between high magnesium levels and superior outcomes, including less and milder acute graft-versus-host disease, which does not affect cyclosporine-A levels. These findings provide valuable information for identifying the risk of poor prognosis in patients preparing for transplantation.

查看原文本刊更多论文

同种异体造血细胞移植前的镁水平对急性白血病预后的影响。

本研究评估了血清镁水平的影响及其在急性白血病异基因造血细胞移植（allo-HSCT）结果中的作用。54名接受异基因造血干细胞移植的急性白血病患者根据移植前血清镁水平被分为两组。结果显示，血清镁水平是影响接受allo-HSCT患者预后的一个独立因素。与高镁水平相比，低镁水平与较差的总生存率和无事件生存率相关（总生存率 HR = 0.149; (95% CI: 0.029-0.755; HR = 0.369; 95% CI: 0.144-0.949, 无事件生存率 p = 0.039）。竞争风险模型显示，高镁组急性移植物抗宿主疾病的累积发病率明显较低（P = 0.028）。总体而言，高镁水平与较好的预后之间存在相关性，包括急性移植物抗宿主病的发生率较低且病情较轻，但这并不影响环孢素-A的水平。这些发现为确定准备接受移植的患者预后不良的风险提供了宝贵的信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplant immunology 医学-免疫学

CiteScore

2.10

自引率

13.30%

发文量

198

审稿时长

48 days

期刊介绍： Transplant Immunology will publish up-to-date information on all aspects of the broad field it encompasses. The journal will be directed at (basic) scientists, tissue typers, transplant physicians and surgeons, and research and data on all immunological aspects of organ-, tissue- and (haematopoietic) stem cell transplantation are of potential interest to the readers of Transplant Immunology. Original papers, Review articles and Hypotheses will be considered for publication and submitted manuscripts will be rapidly peer-reviewed and published. They will be judged on the basis of scientific merit, originality, timeliness and quality.